Toward an HIV type 1 vaccine that generates potent, broadly cross- reactive neutralizing antibodies

AIDS Research and Human Retroviruses

Volumn 15, Issue 8, 1999, Pages 689-698

  Montefiori, David C ^a   Evans, Thomas G ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CONFERENCE PAPER; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; VACCINE PRODUCTION;

AIDS VACCINES; ANIMALS; CROSS REACTIONS; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; NEUTRALIZATION TESTS;

EID: 0033586988     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310773     Document Type: Conference Paper

References (93)

1. Letvin NL: Progress in the development of an HIV-1 vaccine. Science 1998;280:1875-1880.
2. Burton DR and Montefiori DC: The antibody response in HIV-1 infection. AIDS 1997;11:S87-S98.
3. Haynes BF, Pantaleo G, and Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-328.
4. Egan MA, Pavlat WA, Tartaglia J, Paoletti E, Weinhold KJ, Clements ML, and Siliciano RF: Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1 MN env gene. J Infect Dis 1995;171:1623-1627.
5. Ferrari G, Humphries W, McElrath MJ, Excler J-L, Duliege A-M, Clements M-L, Corey LC, Bolognesi DP, and Weinhold KJ: Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-1401.
6. Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler J-L, Duliege A-M, Tartaglia J, McNamara J, Kai-Lin H, Montefiori D, and Weinhold K: Rapid induction of HIV-1 immune responses by canarypox (ALVAC) HIV-1 and gp120 SF2 recombinant vaccines in uninfected volunteers. AIDS 1998;12:2407-2415.
7. Korber BTM, Allen EE, Farmer AD, and Myers GL: Heterogeneity of HIV-1 and HIV-2. AIDS 1995;9:S5-S18.
8. Chan DC, Fass D, Berger JM, and Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
9. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, and Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature (London) 1997;387:426-430.
10. Kwon PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (London) 1998;393:648-659.
11. Wyatt R, Kwon PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, and Sodroski JG: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (London) 1998;393:705-711.
12. Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998;280:1884-1888.
13. Chan DC and Kim PS: HIV entry and its inhibition. Cell 1998; 93:681-684.
14. Graham BS: Serologic responses to candidate AIDS vaccines. AIDS Res Hum Retroviruses 1994;10(Suppl. 2):S145-S148.
15. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements M-L, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, and Burke DS: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348.
16. Hanson CV: Measuring vaccine-induced HIV neutralization: Report of a workshop. AIDS Res Hum Retroviruses 1994;10:645-648.
17. Matthews TJ: Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses 1994;10:631-632.
18. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF, Burton DR, and Ho DD: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101-109.
19. D'Souza MP, Livnat D, Bradac JA, and Bridges SH: Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials: J Infect Dis. 1997;175:1056-1062.
20. Montefiori DC, Zhou J, Barnes B, Lake D, Hersh EM, Masuho Y, and Lefkowitz LB Jr: Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology 1991;182:635-643.
21. Sawyer LSW, Wrin MT, Crawford-Miksza L, Potts B, Wu Y, Weber PA, Alfonso RD, and Hanson CV: Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994;68:1342-1349.
22. Wrin T, Loh TP, Vennari JC, Schuitemaker H, and Nunberg JH; Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 1995;69:39-48.
23. Kostrikis LG, Cao Y, Ngai H, Moore JP, and Ho DD: Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996;70:445-458.
24. Moore JP, Cao Y, Leu J, Qin L, Korber B, and Ho DD: Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996; 70:427-444.
25. VanCott TC, Polonis VR, Loomis LD, Michael NL, Nara PL, and Birx DL: Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses 1995;11:1379-1391.
26. Moog C, Fleury HJA, Pellegrin I, Kirn A, and Aubertin AM: Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997;71:3734-3741.
27. Zolla-Pazner S and Sharpe S: A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res Hum Retroviruses 1995;11:1449-1457.
28. Zhou JY and Montefiori DC: Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J Virol 1997;71:2512-2517.
29. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, and Montefiori DC: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term nonprogressive infection. J Infect Dis 1997;176:924-932.
30. Spenlehauer C, Saragosti S, Fleury HJA, Kirn A, Aubertin A-M, and Moog C: Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. J Virol 1998;72:9855-9864.
31. Montefiori DC, Collman RG, Fouts TR, Zhou JY, Bilska M, Hoxie JA, Moore JP, and Bolognesi DP: Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol 1998;72:1886-1893.
32. Trkola A, Ketas T, KewalRamani VN, Endorf F, Binley JM, Katinger H, Robinson J, Littman DR, and Moore JP: Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of their coreceptor usage. J Virol 1998;72:1876-1885.
33. LaCasse RA, Follis KE, Moudgil T, Trahey M, Binley JM, Planelles V, Zolla-Pazner S, and Nunberg JH: Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J Virol 1998;72:2491-2495.
34. Sullivan N, Sun Y, Li J, Hofmann W, and Sodroski J: Replication function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 1995;69:4413-4422.
35. Watkins BA, Buge S, Aldrich K, Davis AE, Robinson J, Reitz MS Jr, and Robert-Guroff M: Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J Virol 1996;70:8431-8437.
36. Fouts TR, Binley JM, Trkola A, Robinson JE, and Moore JP: Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glyeoprotein complex. J Virol 1997;71:2779-2785.
37. Moore JP and Binley J: Envelope's letters boxed into shape. Nature (London) 1998;393:630-631.
38. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, and Norcross MA: Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;6006-6013.
39. Kimpton J and Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J Virol 1992;66:2232-2239.
40. Wild C, Greenwell T, and Matthews T: A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9:1051-1053.
41. Burns DPW and Desrosiers RC: A caution on the use of SIV/HIV gag antigen detection systems in neutralization assays. AIDS Res Hum Retroviruses 1992;8:1189-1192.
42. Mondor I, Ugolini S, and Sattentau QJ: Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparins. J Virol 1998;72:3623-3634.
43. Cecilia D, Kewalramani VN, O'Leary J, Volsky B, Nyambi P, Burda S, Xu S, Littman DR, and Zolla-Pazner S: Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 1998;72:6988-6996.
44. Hill CM, Deng H, Unutmaz D, Kewalramani VN, Bastiani L, Gorny MK, Zolla-Pazner S, and Littman DR: Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J Virol 1997;71:6296-6304.
45. + T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 1995;69:3712-3720.
46. Berger EA: HIV entry and tropism: The chemokine receptor connection. AIDS 1997;11:S3-S16.
47. Krause RM, Dimmock NJ, and Morens DM: Summary of an antibody workshop: The role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases. J Infect Dis 1997;176:549-559.
48. Prince AM, Reesink H, Pascual D, Horowitz B, Hewlett I, Murthy KM, Bobb KE, and Eichberg JW: Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 1991;7:971-973.
49. Emini EA, Schleiff WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, Eichberg JW, and Murthy KK: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (London) 1992;355:728-730.
50. Conley AJ, Kessler JA II, Boots LJ, McKenna PM, Schleif WA, Emini EA, Mark GE III, Katinger H, Cobb EK, Lunceford SM, Rouse SR, and Murthy KK: The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 1996;70:6751-6758.
51. Gauduin M-C, Parren PWHI, Weir R, Barbas CF, Burton DR, and Koup RA: Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nature Med 1997;3:1389-1393.
52. Lu Y, Pauza CD, Lu X, Montefiori DC, and Miller CJ: Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:6-18.
53. +-B-cell changes predict rapid disease progression after simian-human immunodeficiency virus infection macaques. J Virol 1998;72:1600-1605.
54. Mascola JR, Louder MK, VanCott TC, Sapan CV, Lambert JS, Muenz LR, Bunow B, Birx DL, and Robb ML: Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol 1997; 71:7198-7206.
55. Clements JE, Montelaro RC, Zink MC, Amedee AM, Miller S, Trichel AM, Jagerski B, Hauer D, Martin LN, Bohm RP, and Murphey-Corb M: Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 1995;69:2737-2744.
56. Foresman L, Jia F, Li Z, Wang C, Stephens EB, Sahni M, Narayan O, and Joag SV: Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. AIDS Res Hum Retroviruses 1998;14:1035-1043.
57. Shibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Med 1999;5:204-210.
58. Haigwood NL, Watson A, Sutton WF, McClure J, Lewis A, Ranchalis J, Travis B, Voss G, Letvin NL, Hu S-L, Hirsch VM, and Johnson PR: Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile. Immunol Lett 1996;51:107-114.
59. Earl PL, Doms RW, and Moss B: Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA 1990;87:648-652.
60. Lu M, Blacklow SC, and Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nature Struct Biol 1995;2:1075-1082.
61. Weissenhorn W, Wharton SA, Calder LJ, Earl PL, Moss B, Alirandis E, Skehel JJ, and Wiley DC: The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J 1996;15;1507-1514.
62. Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, Wyatt R, and Sodroski J: Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 1997;71:9808-9812.
63. Binley JM, Wyatt R, Desjardins E, Kwong PD, Hendrickson W, Moore JP, and Sodroski J: Analysis of the interaction of antibodies with a conserved, enzymatically deglycosylated core of the HIV-1 gp120 envelope glycoprotein. AIDS Res Hum Retroviruses 1997;14:191-198.
64. Matthews TJ, Wild C, Chen CH, Bolognesi DP, and Greenberg ML: Structural rearrangements in the transmembrane glycoprotein after receptor binding. Immunol Rev 1994;140:93-104.
65. Jones PL, Korte T, and Blumenthal R: Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J Biol Chem 1998;273:404-409.
66. Wild C, Oas T, McDanal C, Bolognesi D, and Matthews T: A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992;89:10537-10541.
67. Wild CT, Shugars DC, Greenwell TK, McDanal CB, and Matthews TJ: Peptides corresponding to a predictive α-helical domain in human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994;91:9770-9774.
68. VanCott TC, Bethke FR, Burke DS, Redfield RR, and Birx DL: Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol 1995;155:4100-4110.
69. Burton DR: A vaccine for HIV type 1: The antibody perspective. Proc Natl Acad Sci USA 1997;94:10018-10023.
70. Burton DR and Moore JP: Why do we not have an HIV vaccine and how can we make one? Nature Med 1998;4:495-498.
71. Li JT, Halloran M, Lord CI, Watson A, Ranchalis J, Fung M, Letvin NL, and Sodroski JG: Persistent infection of macaques with simianhuman immunodeficiency viruses. J Virol 1995;69:7061-7071.
72. Li J, Lord CI, Haseltine W, Letvin NL, and Sodroski J: Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J AIDS 1993;5:639-646.
73. Reimann KA, Li JT, Voss G, Lekutis C, Tenner-Racz K, Racz P, Lin W, Montefiori DC, Lee-Parritz DE, Lu YC, Collman RG, Sodroski J, and Letvin NL: An env gene derived from a primary HIV-1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol 1996;70:3198-3206.
74. Montefiori DC, Reimann KA, Wyand MS, Manson K, Lewis MG, Collman RG, Sodroski JG, Bolognesi DP, and Letvin NL: Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. J Virol 1998; 72:3427-3431.
75. Reitter JN, Means RE, and Desrosiers RC: A role for carbohydrates in immune evasion in AIDS. Nature Med 1998;4:679-684.
76. Chackerian B, Rudensey LM, and Overbaugh J: Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 1997;71:7719-7727.
77. Mne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition. J Virol 1998;72:209-217.
78. Back NKT, Smit L, de Jong J-J, Keulen W, Schutten M, Goudsmit J, and Tersmette M: An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 1994;199:431-438.
79. Schønning K, Jansson B, Olofsson S, Neilsen JO, and Hansen J-E S: Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quanternary structure of the HIV-1 envelope oligomer. Virology 1996;218:134-140.
80. Schønning K, Jansson B, Olofsson S, and Hansen J-ES: Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. J Gen Virol 1996;77:753-758.
81. Schønning K, Bolmstedt A, Novotny J, Søgaard Lund O, Olofsson S, and Hansen J-ES: Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120. AIDS Res Hum Retroviruses 1998;14:1451-1456.
82. Reitter JN and Desrosiers RC: Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope glycoprotein. J Virol 1998;72:5399-5407.
83. Bolmstedt A, Sjolander S, Hansen J-ES, Åkerblom L, Hemming A, Hu SL, Morein B, and Olofsson S: Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:213-220.
84. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, and Nunberg JH: Fusion-competent vaccines: Broad neutralization of primary isolates of HIV. Science 1999;283:357-362.
85. Montefiori DC, Hirsch VM, and Johnson PR: AIDS response. Nature (London) 1991;354:440-441.
86. Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, and Bolognesi DP: The ability of certain SIV vaccines to provoke reactions against normal cells. Science 1992;255:292-293.
87. Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, and Bolognesi DP: Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res Hum Retroviruses 1992;8:1641-1652.
88. Cranage MP, Polyanskaya N, McBride B, Cook N, Ashworth LAE, Dennis M, Baskerville A, Greenaway PJ, Corcoran T, Kitchen P, Rose J, Murphey-Corb M, Desrosiers RC, Stott EJ, and Farrar GH: Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses 1993;9:13-22.
89. Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, and Johnson PR: Complement control proteins, CD46, CD55 and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 1994;205:82-92.
90. Montefiori DC and Moore JP: HIV vaccines: Magic of the occult? Science 1999;283:336-337.
91. Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, and Hanson CV: Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1994;7:211-219.
92. + T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998;12:1591-1600.
93. Bradney AP, Scheer S, Crawford JM, Buchbinder SP, and Montefiori DC: Neutralization-escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J Infect Dis 1999;179: in press.